Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-catenin-interacting protein 1 (CTNNBIP1) is a regulatory protein encoded by the human *CTNNBIP1* gene. Its main function is to bind β-catenin and prevent its interaction with TCF family transcription factors, thereby negatively regulating the Wnt/β-catenin signaling pathway. CTNNBIP1 is essential in controlling processes such as cell proliferation, migration, and gene transcription. It acts as a tumor suppressor in various cancers, particularly lung cancer and hepatocellular carcinoma, by inhibiting the transcriptional activation of β-catenin target genes like c-Myc, cyclin D1, and MMP7. Reduced CTNNBIP1 expression is associated with increased cancer cell migration, poorer prognosis, and higher expression of β-catenin target genes. CTNNBIP1 may serve as a prognostic biomarker in cancer, but there are currently no known drugs that directly target CTNNBIP1. It is not classified as a conventional receptor, enzyme, or transporter, but as a regulatory adaptor protein within the Wnt signaling cascade.
Inhibition of Wnt/β-catenin pathway
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-catenin-interacting protein 1 (CTNNBIP1).